Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells

Cells. 2024 Mar 8;13(6):479. doi: 10.3390/cells13060479.

Abstract

Extracellular vesicles (EVs) are small lipid particles secreted by almost all human cells into the extracellular space. They perform the essential function of cell-to-cell communication, and their role in promoting breast cancer progression has been well demonstrated. It is known that EVs released by triple-negative and highly aggressive MDA-MB-231 breast cancer cells treated with paclitaxel, a microtubule-targeting agent (MTA), promoted chemoresistance in EV-recipient cells. Here, we studied the RNA content of EVs produced by the same MDA-MB-231 breast cancer cells treated with another MTA, eribulin mesylate. In particular, we analyzed the expression of different RNA species, including mRNAs, lncRNAs, miRNAs, snoRNAs, piRNAs and tRNA fragments by RNA-seq. Then, we performed differential expression analysis, weighted gene co-expression network analysis (WGCNA), functional enrichment analysis, and miRNA-target identification. Our findings demonstrate the possible involvement of EVs from eribulin-treated cells in the spread of chemoresistance, prompting the design of strategies that selectively target tumor EVs.

Keywords: RNA-seq; eribulin; extracellular vesicles (EVs); miRNAs; microtubule-targeting agents (MTAs).

MeSH terms

  • Breast Neoplasms* / pathology
  • Extracellular Vesicles* / metabolism
  • Female
  • Furans
  • Humans
  • Ketones*
  • MicroRNAs* / genetics
  • Polyether Polyketides*

Substances

  • eribulin
  • MicroRNAs
  • Furans
  • Polyether Polyketides
  • Ketones

Grants and funding

This research was supported by EISAI S.r.l., Milano, Italy.